We sought to develop and validate the performance of a model based on lymphocyte subpopulation of CD4+ T cells, CD8+ T cells, B cells, and NK cells from flow cytometric analysis of pre-treatment blood samples of patients with EGFR-TKI-resistant, EGFR-mutant NSCLC for predicting the PFS outcomes with Chemo+ICI in both training and independent validation cohorts (Figure S10). Here, EGFR is linked to non-small cell lung carcinoma.